A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage
10.3760/cma.j.issn.0253-3766.2019.09.010
- VernacularTitle: 65例早期阑尾源性腹膜假性黏液瘤临床分析
- Author:
Ruiqing MA
1
;
Ao XIA
;
Xichao ZHAI
;
Feng CHEN
;
Hongbin XU
Author Information
1. Department of myxoma, Aerospace Central Hospital, Beijing 100049, China
- Publication Type:Clinical Trail
- Keywords:
Pseudomyxoma peritonei;
Cytoreductive surgery;
Hyperthermic intraperitoneal chemotherapy;
Single center;
Early stage
- From:
Chinese Journal of Oncology
2019;41(9):698-702
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy and safety of cytoreduction surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) in the early stage.
Methods:The clinical data, including pathological features, recurrence and survival of 65 PMP patients in the early stage underwent CRS combined with HIPEC in Aerospace Center Hospital from January, 2011 to December, 2018 were retrospectively analyzed.
Results:65 patients with early stage PMP underwent CRS+ HIPEC. Among these patients, 25 were males and 40 were females, and the mean age was 52.5 years. The median peritoneal cancer index was 3 (0-16). The score of completeness of cytoreduction (CC) of 63 patients (96.9%) was 0, and 2 patients (3.1%) was 1. No perioperative death occurred, the incidence of surgical complications above grade 3 was 3.1%. Three patients relapsed during the follow-up period, including 1 patient with low-grade PMP, 1 patient with high-grade PMP, and 1 patient with high-grade PMP accompanied by signet ring cell. The 5-year disease-free survival rate of the whole group was 92.4%.
Conclusions:PMP patients in the early stage treated by CRS combined with HIPEC can achieve benefit and safety. A close long-term follow-up is necessary.
